COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory ...
The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The ...
Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress immune responses, does not adequately control elderly-onset rheumatoid ...
A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of U.S. and Japanese scientists won the Nobel Prize in physiology or medicine ...
Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded ...
3D rendering of the tumor microenvironment. The recipe for a general and long-lasting cancer treatment could involve regulatory T cells, a type of white blood cell. This is the first installment in a ...
Regulatory T cells (Tregs) could be developed into ‘living drugs’ capable of restoring immune tolerance and treating a wide ...
"Peacemaker" immune cells could help treat diseases ranging from type 1 diabetes to neurodegeneration by restoring immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results